Navigation Links
Vantia Therapeutics Raises £4 Million to Fund Clinical Development of its Lead Compounds
Date:7/6/2011

SOUTHAMPTON, England, July 6, 2011 /PRNewswire/ --


Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need, today announces it has raised £4 million ($6.5 million) in a series B round. The round was co-led by Novo A/S and SV Life Sciences, and included MVM Life Science Partners, all existing investors in Vantia. The funds have been raised to advance the development of Vantia's two clinical candidates, VA106483 for nocturia and VA111913 for dysmenorrhoea, both of which are in Phase II trials.

Andrew Crockett, CEO, said: "I am delighted that our investors have committed these further funds to enable us to advance the development of our lead clinical candidates. We believe both these candidates have the potential to be important drugs in patients who currently have limited treatment options."

Dr Martin Edwards, Senior Partner at Novo Ventures and Chairman of Vantia Therapeutics, said: "Vantia has delivered some very encouraging initial clinical results with its lead programmes and we are pleased to continue supporting the Company as it moves these novel compounds forward."

An exploratory Phase II trial of VA111913 in the treatment of dysmenorrhoea (painful periods) showed promising evidence of reduced pain levels in patients receiving the drug candidate. VA111913 was well tolerated in the study and statistically significant differences between VA111913 treatment and placebo were seen for a number of efficacy endpoints, including treatment preference, and a trend to efficacy was seen in all other relevant endpoints. The study also identified a significant target population that derived a substantial reduction in period pain from VA111913 treatment.

VA106483 is currently being investigated as a new treatment for nocturia in a 30-patient clinical trial to evaluate the dose-response in men aged over 65 years with
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vantia Therapeutics Pipeline Continues to Mature
2. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
3. Vantia Therapeutics Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Nonin Medical, a global leader in noninvasive medical monitoring, ... Steve Bucholz will retire May 1. Company founder ... Chief Executive Officer. In addition, Mr. Isaacson will continue ... transition to David Noel , Chief Financial Officer. ... to Nonin Medical,s growth," Mr. Isaacson said. "Under Steve,s ...
(Date:4/17/2015)... Apr. 17, 2015 Research and Markets ... of the "Medical Device Outsourcing - Global ... This report analyzes the worldwide markets ... the following Device Categories: Class I, Class II, ... in the report Include - Radiology, Orthopedic, Neurology, ...
(Date:4/17/2015)... , Apr. 17, 2015 Research and Markets ... the "Medical Equipment Rental and Leasing - Global ... This report analyzes the worldwide markets for Medical ... provides separate comprehensive analytics for the US, ... Rest of World. Annual estimates and forecasts ...
Breaking Medicine Technology:Nonin Medical's Philip Isaacson Expands CEO Role; President and COO Steve Bucholz to Retire May 1 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3Medical Equipment Rental and Leasing Market 2015-2020 - Global Strategic Business Report - Healthcare Spending Slowdown Bodes Well for Medical Equipment Leasing 2
(Date:4/17/2015)... New York (PRWEB) April 17, 2015 ... that allege this class of prescription medications increases ... heart attack, stroke or other life-threatening cardiovascular event ... in U.S. District Court, Northern District of Illinois. ... the U.S. Judicial Panel on Multidistrict Litigation (JPML) ...
(Date:4/17/2015)... 17, 2015 Scientists from the ... team of U.S. and Venezuelan researchers, have discovered ... humans among an isolated tribe of Yanomami Amerindians ... diversity in the Yanomami, previously unexposed to antibiotics ... double that of people living in industrialized countries, ...
(Date:4/17/2015)... Calvary Hospital recently announced Timothy P. Barr will be ... May 11. The Fund directs all fundraising efforts in support ... J. Spinelli, who retired several months ago. , “We are ... the important work that the Fund does every year,” said ... expand and bring our signature care to people who need ...
(Date:4/17/2015)... Jersey City, NJ (PRWEB) April 17, 2015 ... is stored in the posterior pituitary and thought to ... strengthening bonding between couples. To further substantiate this, new ... published in the journal, Nature, and reported by Medical ... does have a powerful influence over maternal social behavior. ...
(Date:4/17/2015)... Mario Badescu Botanical Exfoliating ... facial skin with its unique combination of finely ... energizing botanicals. This cushiony gel-based formula sloughs off ... and inhibit penetration of special treatments, serums, and ... Seeds, This uncommon exfoliating ingredient is an ecologically ...
Breaking Medicine News(10 mins):Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 3Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 4Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3Health News:Timothy P. Barr Appointed Executive Vice President of Calvary Fund 2Health News:Timothy P. Barr Appointed Executive Vice President of Calvary Fund 3Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 3Health News:Mario Badescu Skin Care Launches Botanical Exfoliating Scrub 2
... SWARTZ CREEK, Mich., Aug. 12 Diplomat Specialty Pharmacy announced today ... 500, Inc.,s annual ranking of the fastest-growing private companies in America. ... nation is an amazing achievement, the additional details are even more resounding," stated ... these: , , , Of the ...
... , , , ... a leading provider of managed care market intelligence, reports that ... contracts that will likely shift thousands of enrollees into new ... Health Plan Analysis , Health Plan of Michigan, Molina Healthcare ...
... use of thiazoles could be possible, research suggests , ... to understanding how a recently approved class of antibiotics ... antibiotics, appear to block a cellular protein called FoxM1, ... according to researchers at the University of Illinois at ...
... WHAT: The Cardiovascular Research Foundation has announced ... TCT (Transcatheter Cardiovascular Therapeutics) 2009, the largest global medical ... TCT 2009 will also feature a new session ... the latest developments in EMR and its relevance to ...
... , THE WOODLANDS, Texas, Aug. 12 Medical oncologist and ... lzang, M.D. has joined the US Oncolo g y ... nsive Cancer Centers of Nevada (CCCN), an affiliate of US Oncolog ... will serve as Chair and Medical Director of the Developmental Therapeutics Committee for US Oncology ...
... , , , , ... -- Atherotech, Inc., developer of the VAP Cholesterol Test, ... continues to grow its cardiodiagnostic business. , , ... heart attack and stroke risk, and the Cystatin C test as ...
Cached Medicine News:Health News:Diplomat Specialty Pharmacy Honored By Inc. Magazine As One Of The Nation's Fastest-Growing Companies 2Health News:New Contract Awards May Shift Thousands of Medicaid Enrollees in Michigan 2Health News:CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 2Health News:CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 3Health News:Nicholas Vogelzang, MD, Joins US Oncology Research Network via Comprehensive Cancer Centers of Nevada 2Health News:Nicholas Vogelzang, MD, Joins US Oncology Research Network via Comprehensive Cancer Centers of Nevada 3Health News:Nicholas Vogelzang, MD, Joins US Oncology Research Network via Comprehensive Cancer Centers of Nevada 4Health News:Atherotech Adds New Cardiometabolic Tests Amid Strong 2009 Growth 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: